Personalised Therapies Prove Best for Specific Lung Cancer

Choosing the right initial treatment for advanced EGFR-mutated non-small cell lung cancer (NSCLC) is a complex puzzle. To find the clearest picture, researchers performed a network meta-analysis, a powerful statistical method that combines data from 37 different randomised controlled trials to compare 24 separate treatment regimens.

For the overall patient group, the combination of osimertinib and chemotherapy was best at slowing the cancer's advancement, what scientists call progression-free survival. However, a different duo, amivantamab plus lazertinib, provided the greatest benefit in terms of overall survival.

Crucially, the study showed that the optimal strategy changes for different subgroups. The best treatments for extending life varied significantly between male and female patients, as well as for Asian or elderly patient groups. This work underscores that the most effective cancer care is not one-size-fits-all, but is instead tailored to the individual.